These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19671763)

  • 1. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
    Woodman SE; Trent JC; Stemke-Hale K; Lazar AJ; Pricl S; Pavan GM; Fermeglia M; Gopal YN; Yang D; Podoloff DA; Ivan D; Kim KB; Papadopoulos N; Hwu P; Mills GB; Davies MA
    Mol Cancer Ther; 2009 Aug; 8(8):2079-85. PubMed ID: 19671763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
    Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR
    Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.
    Todd JR; Becker TM; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2013 Jul; 26(4):518-26. PubMed ID: 23582185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
    Guo T; Agaram NP; Wong GC; Hom G; D'Adamo D; Maki RG; Schwartz GK; Veach D; Clarkson BD; Singer S; DeMatteo RP; Besmer P; Antonescu CR
    Clin Cancer Res; 2007 Aug; 13(16):4874-81. PubMed ID: 17699867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.
    Vita M; Tisserand JC; Chauvot de Beauchêne I; Panel N; Tchertanov L; Agopian J; Mescam-Mancini L; Fouet B; Fournier B; Dubreuil P; Bertucci F; De Sepulveda P
    JAMA Dermatol; 2014 Dec; 150(12):1345-9. PubMed ID: 25317746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
    Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
    Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
    Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
    Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
    Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
    J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic implications of KIT in melanoma.
    Postow MA; Carvajal RD
    Cancer J; 2012; 18(2):137-41. PubMed ID: 22453014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIT as a therapeutic target in metastatic melanoma.
    Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
    JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
    Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
    Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
    Kalinsky K; Lee S; Rubin KM; Lawrence DP; Iafrarte AJ; Borger DR; Margolin KA; Leitao MM; Tarhini AA; Koon HB; Pecora AL; Jaslowski AJ; Cohen GI; Kuzel TM; Lao CD; Kirkwood JM
    Cancer; 2017 Jul; 123(14):2688-2697. PubMed ID: 28334439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
    Shah NP; Lee FY; Luo R; Jiang Y; Donker M; Akin C
    Blood; 2006 Jul; 108(1):286-91. PubMed ID: 16434489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potential role for nilotinib in KIT-mutated melanoma.
    Tran A; Tawbi HA
    Expert Opin Investig Drugs; 2012 Jun; 21(6):861-9. PubMed ID: 22500535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
    de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
    Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
    Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
    Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
    Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
    Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.
    Allegra M; Giacchero D; Segalen C; Dumaz N; Butori C; Hofman V; Hofman P; Lacour JP; Bertolotto C; Bahadoran P; Ballotti R
    J Invest Dermatol; 2014 May; 134(5):1473-1476. PubMed ID: 24317392
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase 2 trial of dasatinib in advanced melanoma.
    Kluger HM; Dudek AZ; McCann C; Ritacco J; Southard N; Jilaveanu LB; Molinaro A; Sznol M
    Cancer; 2011 May; 117(10):2202-8. PubMed ID: 21523734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
    Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
    Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.